Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open Label, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Relapsed/Refractory Follicular Lymphoma

NCT07187960 is registered in ClinicalTrials.gov with Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. as lead sponsor.

NCT NCT07187960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07187960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open Label, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Relapsed/Refractory Follicular Lymphoma
Lead sponsor
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 30, 2025
Completion date
February 28, 2029
Enrollment
228 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma